SAN DIEGO, April 6, 2011 /PRNewswire/ — Aethlon Medical, Inc.,
(OTCBB: AEMD) disclosed today that its Chairman and CEO, James A.
Joyce has issued the following letter to shareholders.
(Photo:
http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
To our Shareholders:
On April 1st, we submitted a contract response to the Defense
Advanced Research Projects Agency (DARPA) related to the Dialysis
Like Therapeutics (DLT) program referenced in my last shareholder
letter. In our submission, we proposed to leverage our
technology platform to deliver a dialysis-like therapy that would
address precursors to sepsis, including bacterial toxins, viral
pathogens, and disease enhancing particles transported by exosomes.
We believe our proposal meets goals underlying the DLT
program as the resulting device would target to reduce the
occurrence of sepsis and would provide decision-free and life
saving medical care for the wounded warfighter. Additionally,
we introduced an innovative strategy to deliver our dialysis-like
therapy without the need for anticoagulants, as well as a novel
approach to selectively clear whole bacteria from circulation.
If selected for an award, several larger organizations and
industry thought leaders have agreed to partner with us to advance
our program proposals. It is anticipated that the DLT program
awards will be announced in the next 120 days. We are now
collaborating with our advisors to determine the next contract or
grant opportunity to pursue. Beyond non-dilutive bioterror and
pandemic threat funding opportunities, we are also evaluating
potential responses to new government programs in Hepatitis-C, HIV,
and Cancer.
In addition to navigating government funding opportunities, we
are actively advancing research and clinical initiatives in both
infectious disease and cancer. On the clinical front, I am
pleased to disclose that we our close to submitting our
updated
‘/>”/>
